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Abstract
Background: Tumor genotype plays a crucial role in clinical management of GIST. Whether genetic polymorphism
of KIT may influence GIST patient outcome is unclear.
Methods: We investigated the biological and clinical significance of the presence of KIT exon 10 variant (c.1621 A > C),
KITL541, in a transfected cell line (3 T3 L541) and in two retrospectively collected series of 109 GIST patients in total. The
control group consisted of 60 healthy donors collected at the French department of blood transfusion.
Results: In the 3 T3 L541 cell line, KITL541 protein exhibited a spontaneous phosphorylation status comparable to that
of wild-type KIT but displayed a phosphorylation pattern of AKT and ERK1/2 that was found similar to that of the
classical mutated forms of the KIT receptor. Of 109 patients enrolled in this retrospective translational research study,
24 (22 %) harboured KITL541, similarly to the control group of healthy donors (n = 10 of 60, 17 %). A higher prevalence
of the variant KITL541 was observed in patients with metastatic status at diagnosis (KITL541 correlated nine of 22 versus
15 of 87, p = 0.02). In addition, patients with KITL541 and localized GIST had a higher rate of relapse at 5 years and lower
relapse free survival at 5 years in univariate, as well as in multivariate analysis. Response rate and duration of response
to imatinib was similar in KITL541 and KITM541 patients.
Conclusion: KITL541 genotype is associated with a higher risk of metastasis at diagnosis and a higher risk of relapse in
GIST patients.
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Background
GIST (gastrointestinal stromal tumors) are the most
common mesenchymal tumors of gastro-intestinal tract
and account for 15 to 20 % of soft tissue sarcomas and 1
to 3 % of all malignant digestive tumors [1]. Their an-
nual incidence is approximately 12–15 cases per million
inhabitants [2, 3]. GIST are paradigmatic models of can-
cers with a driver mutation of an oncogene. These driver
mutations may occur in different genes but are mutually
exclusive: most affect the proto-oncogenes KIT (75-
80 %) and PDGFRA (5–10 %), which encode for mutated
proteins with ligand independent constitutive activation
of tyrosine kinase receptor. There are a variety of KIT
and PDGFRA mutations, on different portions of the re-
ceptors. These different mutations are associated with
different risk of relapse after resection of the primary
tumor but also impact on the activity of imatinib (select-
ive inhibitor of KIT and PDGFR-α) [4–6].
Tumor genotype plays a crucial role in clinical man-
agement of GIST and should now be recommended as a
standard procedure when possible, according to ESMO
guidelines [7]. Beyond these driver mutations, additional
factors such as single nucleotide polymorphism (SNP)
and epigenetic phenomena were found to be associated
with GIST patient outcome [2, 8–12], suggesting the im-
portance of somatic genome.
A SNP of KIT exon ten, encoding for the substitution
of a methionine in position 541 by a leucine (KITL541) in
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the mature KIT protein, has already been reported to be
associated with several diseases, including aggressive
fibromatosis (AF) [13–15], chronic myelogenous leukemia
(CML) [16], pediatric mastocytosis [17] and more recently
in chronic eosinophilic leukemia [18]. The potential im-
pact of this variant, observed in about 20 % of the popula-
tion, on GIST biology, clinical presentation and response
to treatment has never been explored.
In the present work, the clinical and biological signifi-
cance of the presence of the variant protein in GIST was
investigated using two approaches: first exploring KITL541
signalling in transfected cell lines and then exploring the
prevalence and prognostic value of KITL541 in GIST
patients, investigating 2 distinct series of patients.
Methods
Transfected NIH3T3 cell lines
Murine fibroblast cell lines (NIH3T3) were stably in-
fected with oncoviral vectors containing the full-length
human KIT cDNA either 1) wild-type (WT) with M541,
2) encoding for canonical GIST mutations (del557-558 =
D6 or del564-581 =D54), 3) encoding for both WT KIT
and canonical mutations (WT/D6 orWT/D54), 4) encod-
ing for homozygous polymorphic KIT (1621 A > C =
L541), or 5) with the empty vector (MIGR) [19]. The sta-
bly infected NIH3T3 cells expressed the KIT protein in
two forms: the mature and the immature proteins of 145
and 125 kDa, respectively [19].
Cell culture
Cells were cultured at 37 °C humidified atmosphere con-
taining 5 % CO2 in DMEM with 10 % newborn calf
serum (Life Technologies), 2 % penicillin/streptomycin,
1 mM L-Glu. For transfected cells, medium was supple-
mented with 1/1000 G418 (Invitrogen) to maintain a
selective pressure for vectors’ expression. Fifty ng/mL of
Chinese hamster ovary–mouse rhSCF (recombinant
human Stem Cell Factor, R&D systems) were added for
cells expressing WT KIT, so that both the expression
and the activation state of WT and mutant forms of KIT
were equivalent. Treated cells medium was supple-
mented with 1 μM of Imatinib (Novartis) 24 h before
lysis.
Protein extraction and Western blotting
Cells were lysed in Petri plate using RIPA buffer (10 mM
Tris pH 7.4, 150 mM NaCl, Triton 1 %, DOC 0.5 %, SDS
0,1 %, EDTA 1 mM, 1 mM ortho vanadate) plus protein
inhibitors 30 min at 4 °C. Proteins were quantified using
a Dc protein assay kit (Biorad®). Migration was per-
formed using gradient gel (Invitrogen® NuPAGE® 4–12 %
Bis Tris Midi Gel, 1.0 mm) in NuPAGE® MES SDS
running buffer (Invitrogen®). After electrophoretic separ-
ation, proteins were electrotransferred on a polyvinylidene
difluoride membrane (Millipore®). The membrane was
then blocked for 1 h at room temperature with ECL™
Advance Blocking Agent 0.2 % (GE healthcare Limited®)
in TBS/Tween 0.1 % and primary antibody incubated for
one night at 4 °C. The membrane was washed three times
in TBST 0.1 %, and secondary antibodies were incubated
for 1 h at room temperature. Antibodies characteristics
are presented in Additional file 1: Table S1 online. After
washing, revelation was performed using Lumigen™
TMA-6 reagents (GE healthcare Limited®) and Amersham
Hyperfilm™ ECL (GE healthcare Limited®).
Tumor and blood samples
This study was performed as a retrospective translational
research program on tumor and blood samples of 109
GIST patients. The first series included 87 resected pri-
mary GIST untreated until recurrence and the second
series included 22 metastatic or locally advanced/unre-
sectable at diagnosis GIST. A control group consisted of
60 blood samples from healthy donors collected at the
French department of blood transfusion.
All samples of the 109 patients were obtained from
pathology department:
– Paraffin-embedded tissues samples of 98 GIST, at
initial diagnosis, obtained by biopsy or surgical
excision to establish the diagnosis of the disease
 44 included in “EMS” project [20] from February
2006 to July 2007
 35 patients “off-protocol” treated in Centre Léon
Bérard from May 2004 to June 2012
 19 patients included in “BFR14” trial [21] from
June 2002 to April 2006 (15 patients in whom
dry pellet PBMC corresponding were available)
– Dry pellets of peripheral blood mononuclear
cells (PBMC) frozen of 11 patients included in
“BFR14” trial.
All patients signed informed consent to participate to
research according to the French laws. Of note, for pa-
tients included in the BFR14 study, the protocol and its
connected informed consent form (ICF) were reviewed
and validated by a national ethics committee (CPP Sud-
Est IV); for the others patients, an Institutional Review
Board (The Centre Léon Bérard Clinical Trial Review
Committee) reviewed and agreed with the study protocol
and the ICF.
DNA/RNA extraction
Total DNA and RNA was extracted from tumors and
PBMCs, using QIAmp DNA FFPE Kit, QIAamp RNeasy
FFPE Kit and Universal Kit (Qiagen®, France) according
to the manufacturer’s instructions, and quantified by
spectrophotometry (NanoDrop™ ND-100 instrument,
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Thermo Fisher Scientific, Waltham, MA). After sev-
eral washing with toluene and ethanol, FFPE tumors
were lysed using ATL buffer and proteinase K and
incubating at 56 °C for 24–48 h and 90 °C 1 h.
DNA and RNA extraction was carried out using
QIampMiniElute Spin Column and RNeasy MiniElute
Spin Column.
PBMCs were lysed using RLT buffer and proteinase
K. DNA and RNA extraction was carried out using
AllPrep DNA spin column and Rneasy Mini spin
column.
Competitive Allele-Specific Taqman® PCR (CAST®-PCR) and
sequencing
The detection of the SNP was performed by Competitive
Allele-Specific Taqman® PCR technology provided by
Applied Biosystems®, using the method extensively de-
scribed by Dufresne et al. [15]. We both performed a
CAST®-PCR and a classical sequencing in 13 cases. Poly-
merase chain reaction (PCR) was used to amplify KIT
exon 10. The primers used were designed by Primer
Express and generated by Beckman Coulter Genomics:
5’-GTA-ATC-GTA-GCT-GGC-ATG-ATG-TG-3’ (sense)
and 3’-AAC-CAT-TTA-TTT-GTT-CTC-TCT-CCA-GAG-
5’ (antisense). PCR was carried out using Taq DNA
polymerase (Transgenomic, Omaha, NE, USA) with
the following cycle conditions: denaturation at 95 °C,
followed by 10 cycles at decreasing temperatures be-
tween 66 and 61 °C with a decrement of 0.5 °C per
cycle, and additional extension at 72 °C. The primers
used for sequencing were the same as those used for
amplification. Before sequencing, PCR products were
purified using Centriprep centrifugal filter device (Milli-
pore, Billerica, MA, USA). The purified PCR product was
then subjected to automated sequencing performed by
Beckman Coulter Genomics. Results of that double detec-
tion of the SNP, by sequencing and CAST®-PCR, were al-
ways consistent.
Statistical analysis
Statistics were performed using SPSS statistical soft-
ware (version 15.0 for Windows, SPSS, Inc). Chi-2
test, Fisher’s exact test and multivariate analysis (lo-
gistic regression and Cox model) were performed in
order to:
– Compare KITL541 prevalence in GIST and in the
normal donor series.
– Study the distribution of known prognostic factors
(tumor size, mitotic index and organ site) according
to the presence of the SNP.
– Investigate the possible correlation between KITL541
and clinical and biological characteristics of GIST
(disease stage, mutations, relapse).
Relapse free survival (RFS) and overall survival (OS) of
patients harboring or not KITL541 variant were plotted
using the after Kaplan-Meier method and compared by
log-rank test.
Results
KITL541 and WT KIT have similar phosphorylation status in
NIH3T3 cells
KIT function and phosphorylation status was investi-
gated using western blotting analyses (Fig. 1a). No basal
expression or phosphorylation of KIT was detected in
MIGR cell control. The two forms of the receptor,
125 kDa (immature) and 145 kDa (mature), were found
expressed in WT transfected cells. The 145-kDa form
was found phosphorylated on both Y-823 and Y-703, at a
basal level. The L541 cell line (expressing the poly-
morphic form of KIT, KITL541) displayed the same ex-
pression and phosphorylation pattern as WT cell line
upon SCF stimulation. D6 and D54 transfected mutants
showed an increased spontaneous phosphorylation sta-
tus on both residues. The immature 125-kDa form was
also phosphorylated on both tyrosines but not in cell
lines with WT or L541. In cells transfected with WT and
D6 or D54 mutated KIT, phosphorylation status of both
Y-703 and Y-823 was found increased, in line with re-
ported KIT activation status in tumors exhibiting homo/
heterozygous mutations of the receptor [18]. Overall, in
WT and L541 cell lines, only membrane mature KIT is
phosphorylated upon SCF exposure, while both mature
and immature KIT are constitutively activated in D6 and
D54 cell lines. In all cell lines, Y-823 phosphorylation is
completely lost after imatinib treatment.
Intracellular signaling in KIT-expressing cell lines with or
without imatinib treatment
KIT signaling pathways and the phosphorylation status
of AKT (PI3K-AKT pathway), RAF, ERK1 and ERK2
(MAPK pathway) was assessed in these cell lines.
L541 cell line was found to activate AKT at a similar
level than the D6 and D54 mutants. After imatinib ex-
posure, P-AKT increased in MIGR cell line, remained
stable in WT and D54 cell lines, and decreased in D6
and in L541 cells.
RAF phosphorylation was similar in WT, D6 and D54
cell lines and was not affected by imatinib exposure. In
contrast, the downstream ERK proteins were found to
display phosphorylation, varied according to KIT muta-
tion status: high levels of spontaneous phosphorylation
are detectable in MIGR control, D54, D54/WT and in
L541 cell lines, in particular ERK2 (42 kDa). Lower levels
are observed in D6 cell lines cells whereas it is undetect-
able in WT cell lines. Exposure to imatinib was found to
increase ERK phosphorylation in WT, D6, D54 and WT/
D6 cell lines but not in WT/D54 and L541 cell lines.
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Overall, in L541 cell line, KIT displays an activation pattern
of AKT and ERK1 or 2 similar to that of the mutated forms
of the receptors in presence of SCF. We conclude that
KITL541 share some of the biochemical properties of the
mutated KIT receptors
The association between the presence of the variant
KITL541 and clinical presentation and prognostic in GIST
patients was then investigated.
Clinical and biological characteristics of the two GIST
patients series
This retrospective case–control study was conducted on
two different series: 87 resected primaries GIST un-
treated until recurrence and 22 metastatic at diagnosis
(or locally advanced/unresectable) GIST. The character-
istics of the two series of GIST are presented in Table 1.
Within the first series, clinical and biological charac-
teristics are similar to those described in literature, with
a median age at diagnosis at 65 years old (range = 22–
84), a sex ratio about 1 (42/45), a majority of gastric
location (n = 52, 60 %) and a majority of KIT exon 11
mutation (n = 40, 54 %). With a median follow-up of
68 months, there were 17 (20 %) local or metastatic re-
lapse at 5 years: 7 of 12 (59 %) KIT exon 11 mutated, 1
of 12 (8 %) KIT exon nine mutated, 1 of 12 (8 %) KIT
exon 13 mutated, 2 of 12 (17 %) with mutations in
PDGFRA (exon 18, D842V), 1 of 12 (8 %) WT and five
with an undetermined mutational status.
As expected, tumor’s parameters of the second series
(size, location and mitotic rate) were worse according to
Miettinen classification: higher median size (90 mm,
range 45–240, versus 58 mm, range 17–400), higher mi-
totic rate and more small bowel location (n = 11, 50 %,
versus n = 24, 28 %).
In the control group of 60 healthy blood donors, the
sex ratio was 1 (30/30) and the median age was 45 years
old (range 19–63).
Clinical and biological impact of the L541 KIT variant
Of all 109 patients, 24 (22 %) harboured KITL541, simi-
larly to the control group of healthy donors (n = 10 of
60, 17 %; Chi-squared test, p = 0.4). The variant was al-
ways detected in both GIST tumor cells and dry pellets
PBMC when both types of samples were available (n =
Fig. 1 KIT maturation and activation status and related intracellular signaling in KIT-expressing cells treated or not with imatinib. Western blotting
analysis after a 24-h exposure to 1 μM of imatinib of the expression and the phosphorylation of a. mature (145 kDa) and immature (125 kDa)
forms of KIT on residues Tyr703 and Tyr823 and b. AKT, RAF and ERK1/2
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15), confirming that it is not a mutation but a somatic
genetic variant. Distribution of the clinical and biological
characteristics of GIST harboring or not KITL541 are de-
tailed in Table 2, showing no differences between those
2 groups regarding size, the location, the mitotic index
and the distribution of KIT and PDGFRA mutations. Im-
portantly, prevalence of KITL541 was statistically higher
in this series of GIST patients metastatic at diagnosis vs
non-metastatic patients at diagnosis (n = 9/22, 41 % ver-
sus n = 15/87, n = 17 %; Fischer’s exact test, p = 0.02).
In the first series of 87 non-metastatic patients, 15 had a
KITL541 (17 %). KITL541 was significantly correlated to a
higher rate of local or metastatic relapse at 5 years (n = 7/
15, 47 %, versus n = 10/72, 14 %; Fisher’s exact test, p =
0.008), resulting in a lower relapse free survival (RFS)
(Fig. 2a; Log-rank test, p =0.001).
Importantly, in multivariate analysis (KITL541 status,
tumor size, location, mitotic index and mutation status)
using Cox model, KITL541 was independently and dir-
ectly associated to a lower RFS at 5 years (p = 0.004), to-
gether with tumor size (< or ≥ 50 mm, p = 0.03) and
mitotic rate (< or ≥ 5 per 50 HPF, p = 0.006) (Table 3).
L541 KIT was not correlated to the nature of the driver
mutation.
Overall survival of the 2 groups was not significantly
different (Fig. 2b; Log-rank test, p = 0.3). In the subgroup
of WT and PDGFRA mutated GIST, KITL541 was associ-
ated to a lower RFS at 5 years (Log-rank test, p = 0.02).
In the subgroup of KIT mutated GIST, RFS of the 2
groups was not different although a trend was observed
(Log-rank test, p = 0.09).
In the second series of 22 metastatic GIST at diagno-
sis, PFS and OS at 5 years of the patients harbouring or
not KITL541 were not different (Log-rank test, p = 0.2
and p = 0.6). Pooling this series of patients with all 24 re-
lapsing patients from group 1 (17 relapses at 5 years and
seven beyond 5 years) yield a group of 46 patients. In
this pooled series as well, PFS and OS at 5 years of the
metastatic patients receiving imatinib and harbouring or
not KITL541 were also not significantly different (Log-
rank test, p = 0.6 and p = 0.6) indicating that KITL541 is a
prognostic factor for relapse but not a predictive factor
for response to imatinib.
Discussion
In this work, we investigated the biological and clinical
significance of the SNP KITL541 in GIST patients, its po-
tential role in carcinogenesis and the potential predictive
value of this variant for GIST patients outcome.
Using transfected cell lines, KITL541 was found to ex-
hibit a similar maturation and activation pattern than
WT KIT but induced a mutant-like intracellular signal-
ling in the presence of SCF. The role of the transmem-
brane domain in tyrosine kinase receptors dimerization
and signalling is well known and mutations in this re-
gion can result in constitutive activation [22, 23]. The in
vitro experiments of this study suggest that cells express-
ing KITL541 may have a proliferative and survival advan-
tage. The substitution of a methionine into a leucine in
position 541, at the end of the transmembrane domain,
seems to increase the ability of the receptor to activate
PI3K/AKT and MAPK signalling pathways as compared
with WT KIT.
The prevalence of this variant was investigated in two
series of GIST patients and in a control group. KITL541
was both detected in tumors and PBMCs DNA; it is a
constitutional SNP variant unlike activating mutations of
KIT and PDGFRA. We reported in this study a similar
prevalence of KITL541 in healthy donors and GIST pa-
tients. This SNP is not associated with specific activating
Table 1 Baseline characteristics of the two retrospective series
of GIST









Age (years) 65 (22–84) 64 (39–79)
Median size (mm) 58 (17–400) 90 (45–240)
Location
Stomach 52 (60 %) 8 (36 %)
Small bowel 24 (28 %) 11 (50 %)
Other locations 11 (12 %) 3 (14 %)
Mitotic index per 50 HPF
≤ 5 51 (59 %)a 5 (26 %)a
6–10 12 (14 %)a 4 (21 %)a
> 10 23 (27 %)a 10 (52 %)a
Unknown 1 3
Mutation status
KIT ex 11 40 (54 %)a 12 (75 %)a
KIT ex 9 5 (7 %)a 3 (19 %)a
KIT ex 13 1 (1 %)a 1 (6 %)a
KIT ex 17 2 (3 %)a 0
PDGFRA ex 18 11 (15 %)a 0
D842V 9 0
No mutation on KIT or
PDGFRA hotspots
15 (20 %)a 0
Unknown 13 6
Prevalence of the variant
KITL541
15 (17 %) 9 (41 %)
aPercentages are determined on the evaluable cases
HPF high-power field
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mutations of KIT or PDGFRA and the proportion of
KITL541 does not differ between WT GIST and other.
These results suggest that KITL541 is not per se a risk
factor for GIST development. However, KITL541 was
found associated with a higher risk of tumor progression
and dissemination. In the first series of GIST patients,
KITL541 was associated with a higher risk of relapse,
resulting in a lower relapse-free survival at 5 years.
Importantly, this impact of KITL541 was conserved in
multivariate analysis using Cox model. Moreover,
KITL541 prevalence was higher in patients presenting
with metastatic GIST at diagnosis. These results sug-
gest that this variant is a prognostic factor for relapse
and progression.
Conversely, KITL541 was not found to be a predictive
biomarker for the efficacy of imatinib in advanced phase.
However, it must be noted that the power of the study
remained limited by the small size of the cohort treated
by imatinib, as well as subgroup analysis in subgroup of
WT and PDGFRA mutated GIST (6 cases) could not be
performed.
Sequence variations (SNP) of KIT have been described
to play an important role in cancer. Rare SNP on KIT
exon 10 (A533D and F522C) are identified in systemic
aggressive mastocytosis [24] and lead to constitutive ac-
tivation of the receptor. This variant (c.1621 A > C) in
exon 10 of KIT (KITL541) has previously been described
Table 2 Clinical and biological characteristics of the two GIST
patients series according to KITL541
Clinical and biological characteristics KITL541 KITM541 Pb
N 24 85
Median size (mm) 50 (17–240) 60 (20–400)
Location
Stomach 12 (50 %) 48 (56 %) 0.6
Small bowel 7 (29 %) 28 (33 %) 1
Mitotic index
≤ 5 11 (50 %)a 46 (54 %) 0.8
6–10 2 (9 %)a 15 (18 %) 0.5
> 10 9 (41 %)a 24 (28 %) 0.4
Mutation status
KIT Mutations 15 (75 %)a 49 (70 %)a 0.8
KIT exon 11 10 (50 %)a 42 (60 %)a 0.5
KIT exon 9 3 (15 %)a 5 (7 %)a 0.4
KIT exon 13 2 (10 %)a 0 n/a
KIT exon 17 0 2 (3 %)a n/a
PDGFRA Mutations 2 (10 %)a 9 (13 %)a 1
PDGFRA exon 18 D842V 1 8
Wild Type 3 (15 %)a 12 (17 %)a 1
Undetermined 4 15
Stage of the disease at diagnosis
Localized 15 (62 %) 72 (85 %) 0.02
Metastatic (or locally
advanced/unresectable)
9 (38 %) 13 (15 %)
aPercentages are determined on the evaluable cases
bChi-square test or Fisher’s exact test were applied as appropriate to check for
differences according to the presence of KITL541 Fig. 2 a. Kaplan–Meier analysis of RFS at 5 years of the first
retrospective series of primary resected GIST stratified by KITL541
status (p = 0.001); x-axis, time in months. b. Kaplan–Meier analysis of
OS at 5 years of the first retrospective series of primary resected GIST
stratified by KITL541 status (p = 0.3); x-axis, time in months
Table 3 Impact of KITL541, tumor size, location, mitotic index
and mutational status on RFS at 5 years in multivariate analysis
Variable HR (95 % CI) P
KITL541 6.1 (1.8–21) 0.004
Tumor size (<50 mm versus≥ 50 mm) 3.6 (1.1–12) 0.03
Location (gastric versus non gastric) 0.5 (0.1–2) 0.06
Mitotic index per 50 HPF (<5 versus ≥5) 6.2 (1.7–23) 0.006
Mutation status (all other versus KIT exon 11) 1.5 (0.4–5) 0.6
HR Hazard ratio, CI confidence intervals
Brahmi et al. BMC Cancer    Page 6 of 8
in CML, AF, systemic mastocytosis and Merkel cell
carcinoma. Inokuchi and al. [16] performed in vitro ex-
periments on KITL541 Ba/F3 cells, showing that tyrosine
kinase activation and proliferative response of KITL541
cells were slightly higher than WT KIT in medium con-
taining 0.1 ng/ml SCF. Moreover, in a cohort of 80 pa-
tients with CML, KITL541 was associated to a statistically
lower median overall survival [16]. In vitro studies of
Foster et al. [17] demonstrated that FDC-P1 cells trans-
fected with KITL541 showed an enhanced proliferative
response to low levels of stem cell factor (SCF)
(≤6.25 ng/ml). Grabellus et al. [25] showed that preva-
lence of KITL541 in aggressive fibromatosis did not differ
from the general population, suggesting that this variant
was not involved in carcinogenesis of these tumors. In
2006, Gonçalves et al. [13] published the case of a major
tumor response of imatinib, corresponding to a desmoid
tumor expressing KITL541. Conversely, Dufresne et al.
[15] did not observe a predictive value of KITL541 for re-
sponse to imatinib for patients with AF. Currently, the
significance of the KITL541 variant in AF remains un-
clear. More recently, Iurlo et al. [18] suggest that the
presence of KITL541 in chronic eosinophilic leukemia
could be a predictive factor of imatinib sensitivity.
Currently, GIST recurrence potential after complete
surgery resection is measured using a set of predictive
parameters: tumor size, mitotic rate, organ site, tumor
rupture and nature of the driver mutation. These bio-
markers still remain imperfect to identify accurately pa-
tients who will relapse and may be candidate to adjuvant
imatinib treatment. Additional factors such as germline
genetic variations and epigenetic phenomena (DNA hy-
pomethylation and hypermethylation, microRNA alter-
ations, etc.…) were found to be associated with GIST
patient outcome [2, 8–12]. O’Brien et al. [26, 27] investi-
gated the role of inherited genetic SNP in tumor devel-
opment and have identified several SNP associated with
GIST mutation subtypes (for example, CYP1B1 SNP
and, as expected, deletion at KIT exon 11 codons 557–
8). Besides, a few germline genetic variants of receptor
tyrosine kinase (IGF1R, VEGFR) were previously found
to be associated with clinical outcome [2, 9–12], suggest-
ing the importance of somatic genome in GIST. Results
of Angelini et al. [11] suggest that polymorphisms in the
genes coding folate-metabolising enzymes may modify
the risk of GIST and clinical outcome and results of
Haller et al. [28] suggest SPP1 promoter methylation as
a novel and independent prognostic parameter in GIST.
KITL541 belongs to this novel class of predictor of the
risk of relapse in patients with GIST. Its detection could
be useful for clinical management of GIST patients.
However, the way to use those additional prognostic
markers in routine remains unclear and further investi-
gations are necessary.
Conclusion
In conclusion, the variant KITL541 was not found associ-
ated with increased risk of development of GIST but
represents a predictive factor for relapse in localized
GIST. Conversely, KITL541 is not a predictive factor for
response to imatinib in patients with GIST.
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